DocGo, Inc.

How big is DocGo, Inc.?

As of Jun 18, DocGo, Inc. has a market capitalization of 158.57 million and reported net sales of 520.49 million with a net profit of -8.32 million over the latest four quarters. Shareholder's funds are 320.92 million, and total assets amount to 455.62 million.

As of Jun 18, DocGo, Inc. has a market capitalization of 158.57 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 520.49 million for the latest four quarters. During the same period, DocGo, Inc. experienced a net profit of -8.32 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds of 320.92 million and total assets amounting to 455.62 million.

What does DocGo, Inc. do?

DocGo, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $96 million and a net loss of $11 million as of March 2025. It has a market cap of $158.57 million, with key metrics indicating no earnings, a debt-to-equity ratio of -0.13, and a price-to-book ratio of 0.51.

Overview: <BR>DocGo, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 96 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -11 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 158.57 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.13 <BR>Return on Equity: -3.07% <BR>Price to Book: 0.51<BR><BR>Contact Details: <BR>Registrar Address: Not available.

Should I buy, sell or hold DocGo, Inc.?

Is DocGo, Inc. overvalued or undervalued?

As of May 8, 2025, DocGo, Inc. is considered risky and overvalued with a Price to Book Value of 0.49 and an EV to EBITDA ratio of 7.86, significantly underperforming compared to peers and experiencing a year-to-date return of -63.44%.

As of 8 May 2025, the valuation grade for DocGo, Inc. has moved from fair to risky, indicating a deteriorating outlook. The company appears to be overvalued based on its current financial metrics, particularly given its Price to Book Value of 0.49 and an EV to EBITDA ratio of 7.86, which suggests that the market is pricing the company at a premium relative to its earnings potential. Additionally, the EV to Sales ratio stands at 0.22, further reinforcing the perception of overvaluation in the context of its financial performance.<BR><BR>In comparison to its peers, DocGo, Inc. has a significantly lower EV to EBITDA ratio than Fulgent Genetics, Inc. at -8.0743 and Enhabit, Inc. at 10.0951, highlighting its relative underperformance. The company's recent stock performance has been poor, with a year-to-date return of -63.44% compared to a positive 12.22% return for the S&P 500, which underscores the challenges it faces in the current market environment.

Is DocGo, Inc. technically bullish or bearish?

As of September 11, 2025, DocGo, Inc. shows a mildly bearish trend with mixed technical signals, underperforming the S&P 500 significantly with a year-to-date return of -63.44% compared to the S&P 500's 12.22%.

As of 11 September 2025, the technical trend for DocGo, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD is bearish, indicating mixed signals. The Bollinger Bands show a bullish stance on the weekly timeframe but bearish on the monthly. The daily moving averages are mildly bearish, and the KST reflects a mildly bullish weekly trend but bearish monthly. Overall, the indicators suggest a mildly bearish stance with some conflicting signals.<BR><BR>In terms of performance, DocGo has significantly underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -63.44% versus the S&P 500's 12.22%, and a one-year return of -56.09% compared to the S&P 500's 17.14%.